Geerse O P, Hoekstra-Weebers J E H M, Stokroos M H, Burgerhof J G M, Groen H J M, Kerstjens H A M, Hiltermann T J N
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, The Netherlands.
University of Groningen, University Medical Center Groningen, Wenckebach Institute and Netherlands Comprehensive Cancer Organization (IKNL), The Netherlands.
Eur J Cancer. 2017 Feb;72:37-45. doi: 10.1016/j.ejca.2016.11.006. Epub 2016 Dec 23.
Gaining regular insight into the nature and severity of distress by a psychosocial nurse coupled with referral to psychosocial and/or paramedical healthcare provider(s) is an experimental supportive care approach. We sought to examine the effects of this approach on quality of life (QoL), patient's mood and satisfaction, end-of-life care and survival in patients with lung cancer.
Patients with newly diagnosed or recurrent lung cancer starting systemic therapy were randomly assigned to receive usual care or the experimental approach. Patients were followed up at 1, 7, 13 and 25 weeks after randomisation with the EORTC-QLQ-C30, the European Quality of Life-5D, the Hospital Anxiety and Depression Scale and the Patient Satisfaction Questionnaire-III. Primary outcome was the mean change in the EORTC-QLQ-C30 global QoL-score between 1 and 25 weeks.
A total of 223 patients were randomised of whom 111 (50%) completed all four assessments (44% in the usual care group versus 55% in the experimental group). No significant difference was found in the mean change global QoL-score (-2.4, 95% CI: 12.1-7.2; P = 0.61), nor in the other patient-reported outcomes. Fewer patients in the experimental group received chemotherapy shortly before the end-of-life, and median survival was comparable (10.3 versus 10.1 months, P = 0.62). Of the 112 dropouts, 33 died and 79 discontinued participation for other reasons.
This supportive care approach neither improved QoL nor other patient-reported outcomes in patients with lung cancer. However, it reduced the use of chemotherapy shortly before the end of life. Possibly, (late) side effects of systemic therapy may have obscured effects of our intervention on QoL.
NTR3540.
心理社会护士定期深入了解痛苦的性质和严重程度,并将患者转介给心理社会和/或辅助医疗保健提供者,这是一种实验性的支持性护理方法。我们试图研究这种方法对肺癌患者生活质量(QoL)、患者情绪和满意度、临终关怀及生存的影响。
开始接受全身治疗的新诊断或复发性肺癌患者被随机分配接受常规护理或实验性方法。随机分组后1、7、13和25周时,使用欧洲癌症研究与治疗组织生活质量核心问卷(EORTC-QLQ-C30)、欧洲五维健康量表(European Quality of Life-5D)、医院焦虑抑郁量表(Hospital Anxiety and Depression Scale)和患者满意度问卷-III对患者进行随访。主要结局是1至25周期间EORTC-QLQ-C30总体生活质量评分的平均变化。
共有223例患者被随机分组,其中111例(50%)完成了所有四项评估(常规护理组为44%,实验组为55%)。总体生活质量评分的平均变化无显著差异(-2.4,95%置信区间:12.1 - 7.2;P = 0.61),其他患者报告的结局也无显著差异。实验组在临终前接受化疗的患者较少,中位生存期相当(10.3个月对10.1个月,P = 0.62)。在112例退出研究的患者中,33例死亡,79例因其他原因停止参与研究。
这种支持性护理方法既未改善肺癌患者的生活质量,也未改善其他患者报告的结局。然而,它减少了临终前化疗的使用。全身治疗的(晚期)副作用可能掩盖了我们的干预对生活质量的影响。
NTR3540。